Gri bio's gri-0621 demonstrates encouraging safety results at planned interim 6-week analysis in ongoing phase 2a study in idiopathic pulmonary fibrosis (“ipf”)

The independent data monitoring committee (“idmc”) has recommended to continue the study as planned as there are no safety concerns demonstrated in the data reviewed

GRI Ratings Summary

GRI Quant Ranking